Patent ID: 8822654

Claim:
A composition comprising a mutated antithrombin; said mutated antithrobmin having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non mutated antithrombin, or having substantially no anticoagulant activity; said mutated antithrombin having an inhibitory activity selected from the group consisting of: (i) a thrombin inhibitory activity substantially reduced, or substantially lost, with respect to the non mutated antithrombin (ii) a factor Xa inhibitory activity reduced, or substantially lost, with respect to the non mutated antithrombin and (iii) a thrombin inhibitory activity and a factor Xa inhibitory activity substantially reduced, or substantially lost, with respect to the non mutated antithrombin; said mutated antithrombin comprising at: one mutation at position 393 or 394, and a substitution at a glycosylation site at the amino acid at position 96, 135, 155 or 192, the amino acid numbering referring to the antithrombin amino acid sequence represented by SEQ ID NO: 2, or one mutation at position 425 or 426, and a substitution at a glycosylation site at the amino acid at position 128, 167, 187 or 224, the amino acid numbering referring to the antithrombin amino acid sequence comprising the signal peptide, represented by SEQ ID NO: 26, or a deletion of amino acids at positions 393 and 394, the amino acid numbering referring to the antithrombin amino acid sequence represented by SEQ ID NO: 2, or a deletion of amino acids at positions 425 and 426, the amino acid numbering referring to the antithrombin amino acid sequence represented by SEQ ID NO: 26; wherein said composition is for the preparation of a drug intended for the treatment of infection, inflammation or hypoxic injury, in particular sepsis and ischemia/reperfusion related to stroke, ischemia/reperfusion related to surgery and ischemia/reperfusion related to organ transplantation.